Immutep’s Efti Combination Shows Promising Results in Lung Cancer Trial

Immutep Ltd ( (AU:IMM) ) has shared an announcement.

Immutep Limited announced promising results from its INSIGHT-003 trial, demonstrating a 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC) patients treated with a combination of eftilagimod alpha, KEYTRUDA®, and chemotherapy. This novel combination therapy showed significant improvement in response rates across all PD-L1 expression levels compared to historical controls, particularly benefiting patients with PD-L1 TPS below 50%, who represent a high unmet need. The trial’s favorable safety profile and strong efficacy data reinforce Immutep’s confidence in establishing a new standard of care for 1L NSCLC, potentially enhancing its industry positioning and offering significant implications for stakeholders.

The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.92 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.

More about Immutep Ltd

Immutep Limited is a late-stage immunotherapy company focused on developing treatments for cancer and autoimmune diseases. The company specializes in its proprietary soluble LAG-3 protein, eftilagimod alpha (efti), which is designed to stimulate both innate and adaptive immunity. Immutep’s products are under evaluation for various solid tumors, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Efti has received Fast Track designation from the FDA for first-line treatment in HNSCC and NSCLC.

Average Trading Volume: 4,260,857

Technical Sentiment Signal: Sell

Current Market Cap: A$423.5M

Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.